Breaking News, Promotions & Moves

CureVac Names New Chief Business Officer

Thaminda Ramanayake offers more than 15 years of biopharma development and deal-making experience.

Author Image

By: Charlie Sternberg

Associate Editor

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), has appointed Thaminda Ramanayake to the role of Chief Business Officer, effective June 1, 2024.   “Thaminda’s extensive experience in advancing corporate strategy, business development and strengthening strategic partnerships in specific areas will be a tremendous asset to CureVac as we work to progress best-in-class mRNA vaccines and medicines across...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters